2. Tango Therapeutics Inc. (NASDAQ:TNGX)
Number of Hedge Fund Holders — 66
Number of Billionaire Holders — 21
Tango Therapeutics, Inc. (NASDAQ: TNGX) has sharpened its precision-oncology strategy around vopimetostat, an investigational PRMT5 inhibitor being studied in combination with RAS-targeting medicines.
An October 23 update reported an 82% objective response rate among 22 efficacy-evaluable patients with previously treated, MTAP-deleted and RAS-mutant pancreatic cancer receiving vopimetostat plus daraxonrasib. Median progression-free survival had not been reached, and the reported nine-month progression-free survival rate was 88%.
The findings are encouraging, but their setting matters. This was an early-stage study in a small, selected population, and the combination’s contribution requires evaluation in a larger randomized trial. The results should not be treated as proof of superiority over treatments studied in different patient groups.
CEO Malte Peters said the initial clinical activity had been “confirmed with longer follow-up and in a larger patient population.”
Following regulatory discussions, the company planned to initiate a registrational Phase 3 trial in first-line MTAP-deleted pancreatic cancer during the first half of 2027. The proposed study would compare the combination against standard chemotherapy.
A June 30 balance of approximately $1 billion in cash, cash equivalents, and marketable securities provides resources for that transition. Moving into pivotal development can materially increase spending, making financial preparation important alongside response data.
The supplied earlier analyst coverage highlighted potential combination-therapy revenues. Those remain forecasts dependent on clinical success, approval, and commercial arrangements.
For investors evaluating targeted cancer therapy stocks, the next meaningful question is whether the early response signal can hold up in a controlled study with clinically relevant endpoints.
Ranking rationale: Tango Therapeutics, Inc. (NASDAQ: TNGX) ranks second with 21 billionaire holders. Its combination-treatment data, planned pivotal development, and substantial financial resources support the thesis, while the small early-stage dataset leaves significant work ahead.
